Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis

BMC Cardiovascular Disorders

Francesco Violi¹  Ludovica Perri¹  Francesco Angelico¹  Lorenzo Loffredo¹ 

[1] I Clinica Medica, Sapienza University of Rome, Viale del Policlinico 155, Rome, 00161, Italy

关键词: Electrical cardioversion;    Statin;    Atrial fibrillation;   

Others  :  857990
DOI  :  10.1186/1471-2261-12-107

 received in 2012-09-11, accepted in 2012-11-15,  发布年份 2012

【 摘 要 】

Background

Atrial fibrillation (AF) is the most common sustained arrhythmia observed in clinical practice. Electrical cardioversion (EC) is commonly used to restore and maintain sinus rhythm but it is characterized by high rate of recurrences. Several trials analyzed the effects of statins to reduce the recurrences in AF with contradictory results.

Methods

We performed a meta-analysis of the interventional trials with statins in patients with persistent AF to evaluate recurrences after EC. Only randomized controlled trials were included in the analysis. Data sources included: Medline, ISI Web of Science, SCOPUS and Cochrane database (up to June 2012). Data extraction was performed by three authors. Study-specific odds ratios (ORs) were combined using fixed-effects model.

Results

Six studies with 515 patients were included in the analysis. Statins used in the selected trials were: atorvastatin (at dosages ranging from 10 to 80 mg/day), pravastatin (40 mg/day) and rosuvastatin (20 mg/day). AF recurrence after EC occurred in 108/258 (41.8%) of patients treated with statins and in 132/257 (51.3%) patients not on treatment with statins. Compared with control, recurrences were significantly reduced with statin treatment (O.R.: 0.662; 95% C.I., 0.45-0.96; p=0.03); statin treatment was associated with an absolute risk reduction of 0.095 and a number needed to treat of 11.

Conclusions

This review suggests that statin therapy was significantly associated with a decreased risk of recurrence in patients with persistent AF after EC.

【 授权许可】

   
2012 Loffredo et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, et al.: 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 2011, 57(11):1330-1337.
• [2]Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB: Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978, 28(10):973-977.
• [3]Sherman DG: Stroke prevention in atrial fibrillation: pharmacological rate versus rhythm control. Stroke 2007, 38(2 Suppl):615-617.
• [4]Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, et al.: Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) Study. Circulation 2004, 109(12):1509-1513.
• [5]Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347(23):1825-1833.
• [6]Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JG, Kingma JH, Crijns HJ, Van Gelder IC: Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004, 43(2):241-247.
• [7]Chung MK: Randomized trials of rate vs. rhythm control for atrial fibrillation. J Interv Card Electrophysiol 2004, 10(Suppl 1):45-53.
• [8]Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, et al.: 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the american college of cardiology foundation/american heart association task force on practice guidelines developed in partnership with the european society of cardiology and in collaboration with the european heart rhythm association and the heart rhythm society. J Am Coll Cardiol 2011, 57(11):e101-e198.
• [9]Savelieva I, Kakouros N, Kourliouros A, Camm AJ: Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European society of cardiology guidelines. Part I: primary prevention. Europace 2011, 13(3):308-328.
• [10]Savelieva I, Kakouros N, Kourliouros A, Camm AJ: Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European society of cardiology guidelines. Part II: secondary prevention. Europace 2011, 13(5):610-625.
• [11]Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM, Darbar D: Role of inflammation and oxidative stress in atrial fibrillation. Hear Rhythm 2010, 7(4):438-444.
• [12]Ferro D, Franciosa P, Cangemi R, Carnevale R, Pignatelli P, Loffredo L, Perri L, Catasca E, Violi F: Serum levels of vitamin E are associated with early recurrence of atrial fibrillation after electric cardioversion. Circ Arrhythm Electrophysiol 2012, 5(2):327-333.
• [13]Dentali F, Gianni M, Squizzato A, Ageno W, Castiglioni L, Maroni L, Hylek EM, Grandi AM, Cazzani E, Venco A, et al.: Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. A systematic review and meta-analysis. Thromb Haemost 2011, 106(2):363-370.
• [14]Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, Krane V, Macfarlane PW: Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 2011, 342:d1250.
• [15]Wang Z, Zhang Y, Gao M, Wang J, Wang Q, Wang X, Su L, Hou Y: Statin therapy for the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Pharmacotherapy 2011, 31(11):1051-1062.
• [16]Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D: Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008, 51(8):828-835.
• [17]Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17(1):1-12.
• [18]Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6(7):e1000097.
• [19]Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22(4):719-748.
• [20]Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, Gullestad L: Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004, 93(6):780-782.
• [21]Almroth H, Hoglund N, Boman K, Englund A, Jensen S, Kjellman B, Tornvall P, Rosenqvist M: Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur Heart J 2009, 30(7):827-833.
• [22]Ozaydin M, Varol E, Aslan SM, Kucuktepe Z, Dogan A, Ozturk M, Altinbas A: Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006, 97(10):1490-1493.
• [23]Xia W, Yin Z, Li J, Song Y, Qu X: Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol 2009, 32(12):1562-1566.
• [24]Negi S, Shukrullah I, Veledar E, Bloom HL, Jones DP, Dudley SC: Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). J Cardiovasc Electrophysiol 2011, 22(4):414-419.
• [25]Demir K, Can I, Koc F, Vatankulu MA, Ayhan S, Akilli H, Aribas A, Alihanoglu Y, Altunkeser BB: Atorvastatin given prior to electrical cardioversion does not affect the recurrence of atrial fibrillation in patients with persistent atrial fibrillation who are on antiarrhythmic therapy. Med Princ Pract 2011, 20(5):464-469.
• [26]Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
• [27]Tamargo J, Caballero R, Gomez R, Nunez L, Vaquero M, Delpon E: Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacol Ther 2007, 114(1):107-126.
• [28]Dernellis J, Panaretou M: Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005, 150(5):1064.
• [29]Neuman RB, Bloom HL, Shukrullah I, Darrow LA, Kleinbaum D, Jones DP, Dudley SC Jr: Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 2007, 53(9):1652-1657.
• [30]Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM: NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 2006, 8(5–6):691-728.
• [31]Loffredo L: Chronic granulomatous disease. Intern Emerg Med 2011, 6(Suppl 1):125-128.
• [32]Kim YM, Guzik TJ, Zhang YH, Zhang MH, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B: A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005, 97(7):629-636.
• [33]Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM, Alp NJ, Schotten U, Casadei B: Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 2011, 124(10):1107-1117.
• [34]Cangemi R, Celestini A, Calvieri C, Carnevale R, Pastori D, Nocella C, Vicario T, Pignatelli P, Violi F: Different behaviour of NOX2 activation in patients with paroxysmal/persistent or permanent atrial fibrillation. Heart 2012, 98(14):1063-1066.
• [35]Violi F, Loffredo L, Musella L, Marcoccia A: Should antioxidant status be considered in interventional trials with antioxidants? Heart 2004, 90(6):598-602.
• [36]Antoniades C, Demosthenous M, Reilly S, Margaritis M, Zhang MH, Antonopoulos A, Marinou K, Nahar K, Jayaram R, Tousoulis D, et al.: Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J Am Coll Cardiol 2012, 59(1):60-70.
• [37]Cangemi R, Loffredo L, Carnevale R, Perri L, Patrizi MP, Sanguigni V, Pignatelli P, Violi F: Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. Eur Heart J 2008, 29(1):54-62.